SELLAS Life Sciences Group, Inc. (SLS) Financial Analysis & Valuation | Quarter Chart
SELLAS Life Sciences Group, Inc. (SLS)
SLSPrice: $4.76
Fair Value: 🔒
🔒score
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, w... more
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development... more
Description
Shares
| Market Cap | $678.02M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Angelos Stergiou |
| IPO Date | 2008-03-12 | CAGR | — |
| Employees | 15 | Website | www.sellaslifesciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SLS chart loading...
Fundamentals
Technicals
| Enterprise Value | $337.76M | P/E Ratio | -5.3 |
| Forward P/E | -22.94 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 7.28 |
| P/CF Ratio | -18.17 | P/FCF Ratio | -23.88 |
| EPS | $-0.3 | EPS Growth 1Y | -58.59% |
| EPS Growth 3Y | -86.94% | EPS Growth 5Y | -91.45% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.61% | ROA | -0.33% |
| ROCE | -0.38% | Current Ratio | 10.72 |
| Quick Ratio | 10.72 | Cash Ratio | 10.25 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 54.49 | Piotroski Score | 1 |